NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-18-892 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and will include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied.
Funding Opportunity PAR-18-893 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and will include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied.
Notice NOT-DA-18-027 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-18-891 from the NIH Guide for Grants and Contracts. NIDDK utilizes High Impact, Interdisciplinary Science (RC2) grants to support projects that will lay the foundation for new fields of investigation within the mission of NIDDK. The RC2 is envisioned to use an interdisciplinary approach to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This targeted FOA specifically seeks to generate scientific advancements addressing the role of the autonomic nervous system in the regulation of peripheral metabolism and its role in diabetes, obesity and related metabolic disease. Interdisciplinary teams may propose to develop resources in the form of novel tools or methodologies that when applied to the autonomic nervous system will contribute to elucidating its functional role in metabolism. Alternatively, teams may focus on novel approaches to address specific knowledge gaps or scientific questions that will significantly contribute to our understanding of role of the autonomic nervous system in metabolism with the goal of accelerating scientific progress in the treatment and prevention of metabolic disease.
Funding Opportunity RFA-RM-18-028 from the NIH Guide for Grants and Contracts. The ability to isolate and analyze single EVs and their cargoes from human biofluids would provide a unique opportunity to understand the cell or tissue from which their respective exRNAs originate (heterogeneity) and, importantly, add significant depth to our understanding of exRNA communication. The overarching goal of this Funding Opportunity Announcement (FOA) is to develop and demonstrate innovative technologies and reagents towards isolating single EVs and to characterize the exRNA cargos associated with specific EV subpopulations based on cell of origin and their intended target cell. Shedding light on the diversity of exRNAs carried by EVs will allow for a better understanding of the precise role of exRNAs as signaling molecules for both physiological and pathophysiological processes, ultimately accelerating development of exRNAs as therapeutics and diagnostics.
Funding Opportunity RFA-RM-18-027 from the NIH Guide for Grants and Contracts. Circulating extracellular RNAs (exRNAs) can act as endocrine signaling molecules, both locally and systemically, representing a novel paradigm in intercellular communication. ExRNAs are transported in body fluids in association with a variety of carrier vehicles of varying complexity including extracellular vesicles (EVs), ribonucleoproteins (RNPs), and lipoproteins (LPPs). These distinct carriers protect exRNAs from degradation and are thought to contribute to the biodistribution, uptake, and functional impact of exRNAs in target cells. The overarching goal of this Funding Opportunity Announcement (FOA) is to develop and evaluate innovative separation tools, technologies, and approaches that will enable the scientific community to rapidly and reproducibly sort complex biofluids into homogenous carrier populations of EVs, (including EV subsets), RNPs, and LPPs, and that also support high-throughput isolation and analysis of their extracellular RNA content and associated molecular cargo.
Funding Opportunity RFA-RM-18-026 from the NIH Guide for Grants and Contracts. This Limited Competition Funding Opportunity Announcement (FOA) invites an application from the currently funded NIH Common Fund-supported Extracellular RNA Communication Consortium (ERCC) Data Management and Resource Repository (DMRR) to support Stage 2 efforts of this program. The overall programmatic goal of the DMRR is to integrate the efforts of all funded components of the ERCC and serve as a community-wide resource for extracellular RNA (exRNA) standards, protocols, and data.
Funding Opportunity RFA-NS-18-034 from the NIH Guide for Grants and Contracts. Recent advances in endovascular thrombectomy offer a new opportunity to reconsider neuroprotective agents as adjunctive therapies to extend the time window for reperfusion and to improve long-term functional outcome. The purpose of this funding opportunity announcement (FOA) issued by NINDS is to invite applications for the Coordinating Center (CC) for the NIH Stroke Preclinical Assessment Network (SPAN). SPAN will facilitate testing of up to 6 promising neuroprotective drugs or interventions to be given prior to or at the time of reperfusion in experimental models of ischemic stroke (e.g., transient middle cerebral artery occlusion). The CC will work with the awarded network sites (RFA-NS-18-033) and will provide centralized administrative oversight and coordination of all aspects of the network. If successful, this network will accelerate the identification of the most promising neuroprotective therapies for future pivotal clinical trials and span the gap between preclinical and clinical testing, in a cost-and time-effective fashion.
Funding Opportunity RFA-NS-18-033 from the NIH Guide for Grants and Contracts. The goal of this initiative is to accelerate the identification of the most promising neuroprotective therapies, and span the gap between preclinical and clinical testing, by creating a preclinical stroke network to support late stage preclinical parallel testing of promising neuroprotectants to be given prior to or at the time of reperfusion, with clinically relevant long-term outcomes and comorbidities. This approach will help to determine if an intervention can indeed improve outcome as compared to reperfusion alone and/or extend the therapeutic window for reperfusion, in an experimental controlled setting and in a time and cost-effective manner using an adaptive design approach.
Funding Opportunity PAR-18-890 from the NIH Guide for Grants and Contracts. The National Institute on Aging invites revision applications to ongoing NIA-supported Cooperative Agreements in the area of the genetics of Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, and data calling that will support the generation of data for the Alzheimer's Disease Sequencing Project Follow-Up Study.
Funding Opportunity PAR-18-889 from the NIH Guide for Grants and Contracts. This FOA invites the NIA Alzheimer's Disease Genetics Consortium to submit revision and/or renewal applications in the area of the genetics of Alzheimer's Disease.
Funding Opportunity RFA-MH-19-135 from the NIH Guide for Grants and Contracts. The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis and manipulation of complex circuits and provide insights into cellular interactions that underlie brain function. Critical advances in the treatment of brain disorders in human populations are hindered by our lack of ability to monitor and manipulate circuitry in safe, minimally-invasive ways. Clinical intervention with novel cell and circuit specific tools will require extensive focused research designed to remove barriers to delivery of gene therapies. In addition to identification and removal of barriers, the need to specifically target dysfunctional circuitry poses additional challenges. Neuroscience has experienced an impressive influx of exciting new research tools in the past decade, especially since the launch of the BRAIN Initiative. However, the majority of these cutting edge tools have been developed for use in model organisms, primarily rodents, fish and flies. These cutting edge tools, such as viral delivery of genetic constructs, are increasingly adaptable to large brains and more importantly are emerging as potential human therapeutic strategies for brain disorders. A pressing need to develop tools for use in large brains, more directly relevant to the human brain is the focus of this initiative. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Methods to track and monito
Funding Opportunity PAR-18-888 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for core/shared resource/central scientific support scientists. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity.
Funding Opportunity PAR-18-887 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for core/shared resource/central scientific support scientists. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity.
Notice NOT-HS-18-015 from the NIH Guide for Grants and Contracts
Notice NOT-HS-18-014 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-19-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites U54 Cooperative Agreement applications aiming to establish multi-component Alzheimer Centers for the Discovery of New Medicines. The overarching purpose of this Centers program is to improve, diversify and reinvigorate the Alzheimers disease (AD) drug development pipeline by accelerating the characterization and experimental validation of next generation therapeutic targets and, integrating the targets into drug discovery campaigns. In addition, this program aims to de-risk potential therapeutics to the point that industry will invest in them, accelerating the delivery of new drugs to AD patients. To this end, the funded Centers will design, develop and disseminate tools that support target enabling packages (TEPs) for the experimental validation of novel, next generation therapeutic targets, including those emanating from the NIA-funded, target discovery programs such as AMP-AD and, initiate early stage drug discovery campaigns against the enabled targets.
Funding Opportunity RFA-HL-19-006 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to identify and then prospectively evaluate the effectiveness of current practices used by primary healthcare providers to manage patients with asthma. The study will use electronic health record systems to generate and test paradigms for how to best manage asthma in the primary healthcare setting. The Cooperative Agreement awarded through this FOA will support a Clinical Center, which will have primary responsibility for study management, data collection, and conduct of clinical trials. The Clinical Center will work collaboratively with a Bioinformatics Center, funded separately, which will have primary responsibility for data analytical aspects of the study. Overall, the study is intended to identify "best practices", and thereby inform future clinical decisions by primary healthcare providers who care for patients with asthma.
Funding Opportunity RFA-HL-19-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to identify and then prospectively evaluate the effectiveness of current practices used by primary healthcare providers to manage patients with asthma. Investigators will identify management strategies in current use for primary care of asthma by analyzing electronic health records (EHRs) from a nationally representative sample of patients and then prospectively evaluate the paradigms for management that appear to be most effective through EHR-enabled clinical trials. The Cooperative Agreement awarded through this FOA will support a Clinical Center, comprised of a primary care network (PCN), a data management core (DMC), and a clinical consultation center (CCC).
Funding Opportunity RFA-NS-18-041 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the discovery of promising candidate biomarkers that will facilitate the development of non-opioid therapeutic options for the treatment of pain conditions. The goal of this FOA is to encourage a biomarker discovery process that will result in the development of pain biomarkers that can withstand rigorous clinical and analytical validation. It is hoped that an increased availability of rigorous biomarkers for pain will facilitate the discovery and development of transformational non-opioid therapeutics for pain.